Intrexon with its collaborator is currently working to develop targeted allergy treatments through its ActoBiotics® platform
. This novel treatment approach has the potential to increase the efficacy of allergen immunotherapy and is based on allergen-specific tolerance through innovative delivery of allergens expressed and secreted by L. lactis
. A successful Proof of Principle study was conducted in preclinical models to validate the application of the technology to allergens.